Nurix Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Nurix Therapeutics

09/04/2024 21:03

* Nurix Therapeutics Inc  NRIX.OQ   NRIX.O  is expected
to show a
rise in quarterly revenue when it reports  results on April 11
(estimated) for the period ending February 29 2024
    * The San Francisco California-based  company is expected to
report a 31.2% increase in revenue to $16.644 million from
$12.69 million a year ago, according to the mean estimate from
10 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Nurix Therapeutics Inc
is for
a loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $23.00​, above​ its last closing price
of $13.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Nov. 30 2023  0.05        -0.57      -0.77     Missed  -35.1
 Aug. 31 2023  -0.78       -0.76      -0.68     Beat    10
 May. 31 2023  -0.49       -0.56      -0.45     Beat    19.6​
 Feb. 28 2023  -0.86       -0.87      -0.75     Beat    13.6
 ​​Nov.        -0.83       -0.79      -0.87     Missed  -10.3
 30 2022                                                
 Aug. 31 2022  -0.96       -0.98      -0.90     Beat    7.7​
 May. 31 2022  -0.98       -0.99      -1.01     Missed  -2.4
 Feb. 28 2022  -0.89       -0.88      -0.95     Missed  -8.5
 This summary was machine generated April 9 at 20:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)